ANGIODYNAMICS INC (ANGO)

US03475V1017 - Common Stock

8.89  +0.31 (+3.61%)

After market: 8.89 0 (0%)

Fundamental Rating

3

Overall ANGO gets a fundamental rating of 3 out of 10. We evaluated ANGO against 187 industry peers in the Health Care Equipment & Supplies industry. While ANGO seems to be doing ok healthwise, there are quite some concerns on its profitability. ANGO is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANGO has reported negative net income.
ANGO had a negative operating cash flow in the past year.
ANGO had negative earnings in each of the past 5 years.
In multiple years ANGO reported negative operating cash flow during the last 5 years.

1.2 Ratios

ANGO has a Return On Assets of -82.77%. This is in the lower half of the industry: ANGO underperforms 79.14% of its industry peers.
The Return On Equity of ANGO (-123.63%) is worse than 67.91% of its industry peers.
Industry RankSector Rank
ROA -82.77%
ROE -123.63%
ROIC N/A
ROA(3y)-24.22%
ROA(5y)-21.27%
ROE(3y)-36.59%
ROE(5y)-30.72%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ANGO has a Gross Margin of 51.71%. This is comparable to the rest of the industry: ANGO outperforms 44.92% of its industry peers.
ANGO's Gross Margin has declined in the last couple of years.
ANGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.88%
GM growth 5Y-2.46%

More info and screens

5

2. Health

2.1 Basic Checks

ANGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
ANGO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ANGO has more shares outstanding
ANGO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 1.22, we must say that ANGO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.22, ANGO is in line with its industry, outperforming 49.73% of the companies in the same industry.
There is no outstanding debt for ANGO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.22
ROIC/WACCN/A
WACC8.97%

2.3 Liquidity

ANGO has a Current Ratio of 2.25. This indicates that ANGO is financially healthy and has no problem in meeting its short term obligations.
ANGO's Current ratio of 2.25 is on the low side compared to the rest of the industry. ANGO is outperformed by 62.03% of its industry peers.
ANGO has a Quick Ratio of 1.41. This is a normal value and indicates that ANGO is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.41, ANGO is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 1.41

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ANGO have decreased strongly by -216.67% in the last year.
The Revenue for ANGO has decreased by -12.85% in the past year. This is quite bad
ANGO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.35% yearly.
EPS 1Y (TTM)-216.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
Revenue 1Y (TTM)-12.85%
Revenue growth 3Y1.46%
Revenue growth 5Y2.35%
Sales Q2Q%-14.22%

3.2 Future

The Earnings Per Share is expected to grow by 34.05% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.03% on average over the next years.
EPS Next Y-4.62%
EPS Next 2Y17.15%
EPS Next 3Y33.25%
EPS Next 5Y34.05%
Revenue Next Year-3.03%
Revenue Next 2Y2.19%
Revenue Next 3Y5.45%
Revenue Next 5Y7.03%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ANGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ANGO's earnings are expected to grow with 33.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.15%
EPS Next 3Y33.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANGO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANGIODYNAMICS INC

NASDAQ:ANGO (12/20/2024, 8:00:00 PM)

After market: 8.89 0 (0%)

8.89

+0.31 (+3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-03 2024-10-03/bmo
Earnings (Next)01-03 2025-01-03/bmo
Inst Owners80.74%
Inst Owner Change2.6%
Ins Owners6.61%
Ins Owner Change14.85%
Market Cap361.20M
Analysts84.44
Price Target13.26 (49.16%)
Short Float %2.98%
Short Ratio2.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.59%
Min EPS beat(2)26.47%
Max EPS beat(2)64.71%
EPS beat(4)3
Avg EPS beat(4)27.46%
Min EPS beat(4)-15.98%
Max EPS beat(4)64.71%
EPS beat(8)5
Avg EPS beat(8)1.55%
EPS beat(12)7
Avg EPS beat(12)-21.38%
EPS beat(16)11
Avg EPS beat(16)14.56%
Revenue beat(2)0
Avg Revenue beat(2)-2.19%
Min Revenue beat(2)-2.6%
Max Revenue beat(2)-1.79%
Revenue beat(4)0
Avg Revenue beat(4)-3.14%
Min Revenue beat(4)-5.51%
Max Revenue beat(4)-1.79%
Revenue beat(8)0
Avg Revenue beat(8)-2.55%
Revenue beat(12)1
Avg Revenue beat(12)-2.38%
Revenue beat(16)5
Avg Revenue beat(16)-0.75%
PT rev (1m)0%
PT rev (3m)-2.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.33%
EPS NY rev (1m)0%
EPS NY rev (3m)1.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.23
P/FCF N/A
P/OCF N/A
P/B 1.84
P/tB 2.99
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS7.2
BVpS4.84
TBVpS2.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.77%
ROE -123.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.71%
FCFM N/A
ROA(3y)-24.22%
ROA(5y)-21.27%
ROE(3y)-36.59%
ROE(5y)-30.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.88%
GM growth 5Y-2.46%
F-Score5
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.83%
Cap/Sales 2.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 1.41
Altman-Z 1.22
F-Score5
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)16.52%
Cap/Depr(5y)20.29%
Cap/Sales(3y)1.51%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-216.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
EPS Next Y-4.62%
EPS Next 2Y17.15%
EPS Next 3Y33.25%
EPS Next 5Y34.05%
Revenue 1Y (TTM)-12.85%
Revenue growth 3Y1.46%
Revenue growth 5Y2.35%
Sales Q2Q%-14.22%
Revenue Next Year-3.03%
Revenue Next 2Y2.19%
Revenue Next 3Y5.45%
Revenue Next 5Y7.03%
EBIT growth 1Y-46.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year99%
EBIT Next 3Y49.78%
EBIT Next 5Y42.76%
FCF growth 1Y3.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.98%
OCF growth 3YN/A
OCF growth 5YN/A